Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled, 3-Part Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Doses of TRB-061 in Healthy Participants and in Patients With Moderate-to-Severe Atopic Dermatitis

NCT06934252 is registered in ClinicalTrials.gov with TRex Bio, Inc. as lead sponsor.

NCT NCT06934252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06934252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled, 3-Part Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Doses of TRB-061 in Healthy Participants and in Patients With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
TRex Bio, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
May 2, 2025
Completion date
February 29, 2028
Enrollment
115 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

moderate-to-severe atopic dermatitis